All posts by imreal

365 Data Centers Acquires US Colocation and Network Business of Sungard Availability Services


365 DataCenters – Technology Humanized

“This acquisition strategically increases & enhances 365 Data Centers’ market footprint, customer base, data center and network facilities, technical and professional skill set, and revenue and cash flow, all of which benefit our customers, employees, and investors” said 365 CEO, Bob DeSantis.

365 Data Centers, a leading provider of network-centric colocation and related managed services, has announced its acquisition of Sungard Availability Services’ U.S. colocation and network business. This transaction adds eight, primarily high-density, data center facilities across several rapidly expanding edge markets, a network platform capable of delivering a variety of connectivity offerings, and 400 new customers. The new data center facilities are in Alpharetta (GA), Aurora (CO), Carlstadt (NJ), Marlborough (MA), Philadelphia-Downtown (PA), Rancho Cordova (CA), Richardson (TX), and Smyrna (GA).

365 Data Centers provides colocation, network access, network transport, IP transit, direct cloud on-ramp, cloud compute, cloud storage, Disaster-Recovery-as-a-Service (“DRaaS”), Back-up-as-a-Service (“BaaS”), and business continuity services to over 1700 carrier, content, and enterprise customers.

The company operates 20 network-centric data centers in the following, primarily edge, markets: Alpharetta (GA), Aurora (CO), Boca Raton (FL), Bridgewater (NJ), Buffalo (NY), Carlstadt (NJ), Chicago (IL), Commack (NY), Detroit (MI), Fort Lauderdale (FL), Herndon (VA), Nashville (TN), Marlborough (MA), Philadelphia-University City (PA), Philadelphia-Downtown (PA), New York City (NY), Rancho Cordova (CA), Richardson (TX), Smyrna (GA), and Tampa( FL). These data centers are home to 111 carriers with 300 carrier Points-of-Presence (“PoPs”). The company has an additional 100 network PoPs supporting it high-capacity nationwide fiber network with over 450 peering partners.

“365 has experienced tremendous internal and external growth since its inception in 2017, having now doubled the business three times. This acquisition strategically increases and enhances 365 Data Centers’ market footprint, customer base, data center and network facilities, technical and professional skill set, and revenue and cash flow, all of which benefit our customers, employees, and investors” said 365 Data Centers CEO, Bob DeSantis. “We are now focused on quickly integrating these businesses into the 365 Data Centers platform in a seamless manner for our newly acquired customers. By closely collaborating with 100 new customer focused employees that have joined the 365 Team from Sungard, we are already providing our new customers with continuity of service and support.”

The company’s existing equity owners and 365’s lending syndicate, comprised of TD Securities, which served as lead left arranger, and ING Capital LLC, Regions Capital Markets, a division of Regions Bank, and CIT, a division of First Citizens Bank, all serving as joint lead arrangers, funded the transaction.

Lance Hirt, Managing Partner at Stonecourt Capital LP., commented, “With this acquisition, 365 Data Centers continues to invest into the rapid growth in local data processing demand being driven by the confluence of IOT and edge computing.”

Regarding the transaction Matt Kim, Managing Partner of Lumerity Capital, stated, “this acquisition represents another significant milestone for the 365 organization. It has been a true pleasure working with Bob and the team as they execute on the company’s objectives and build a leading, scaled provider of data center services focused on meeting customer needs.”

Margarit Ivanov, Director at TD Securities, commented, “TD and the rest of the lending syndicate are very excited to support 365 on this important acquisition. We look forward to continue backing the company as they continue to grow the business and successfully execute on their plan.”

Polsinelli PC acted as the company’s deal counsel. Shipman & Goodwin LLP served as 365’s finance counsel.

###

About 365 Data Centers:

365 Data Centers is a leading provider of hybrid Data Center solutions in 20 strategic, primarily edge, markets. Along with network-centric Data Centers in Alpharetta (GA), Aurora (CO), Boca Raton (FL), Bridgewater (NJ), Buffalo (NY), Carlstadt (NJ), Chicago (IL), Commack (NY), Detroit (MI), Fort Lauderdale (FL), Herndon (VA), Nashville (TN), Marlborough (MA), Philadelphia-University City (PA), Philadelphia-Downtown (PA), New York City (NY), Rancho Cordova (CA), Richardson (TX), Smyrna (GA), and Tampa

(FL), the company operates a resilient, low latency, nationwide fiber network. 365 serves more than 1,700 customers.

365’s robust, carrier-neutral ecosystem and secure, reliable edge colocation, network, IP, DRaaS, BaaS, cloud computing and storage, and business continuity services help organizations reduce costs, drive innovation, and improve their customer experience. 365 Data Centers supports mission-critical application infrastructure by providing industry leading Service Level Agreement protections and adhering to industry standards such as HIPAA, PCI DSS, SOC 1 Type 2, SOC 2 Type 2, SSAE 18, and ISAE 3402. 365 Data Centers’ corporate office is headquartered in Norwalk, Connecticut.

Visit 365datacenters.com for more information.

365 Data Centers Media Contact:

Mark Kolier – Moddern Marketing Services, LLC

1-212-334-9800 x 111

mark@moddern.com

CMI Media Group Bolsters Innovative Capabilities with Audience Intelligence Group for Pharma and Healthcare Clients


Photo of Liz McShea, Group VP, Fabian Henault, VP, Market Research, and Rick Johnson, VP, Intelligence Solutions, leading CMI Media Group's Audience Intelligence Practice.

The leadership team of CMI Media Group’s Audience Intelligence Practice includes Liz McShea, Group VP, Fabian Henault, VP, Market Research, and Rick Johnson, VP, Intelligence Solutions.

“Our industry often talks about improving patient outcomes and in evolving our Audience Intelligence group we’ve been able to walk the walk,” said Julie Hurvitz Aliaga, EVP, Innovation, Content and Partnerships.

CMI Media Group, a WPP company (NYSE: WPP), has evolved its Audience Intelligence practice to holistically connect audience strategy, marketing/ad research, social intelligence, and data insights further enabling always on-intelligence that drives dynamic content, media-mix optimization and deeper engagements. With a focus on driving clients towards where innovation and data intersect, this forward-thinking mentality will continue to position the company as the leader in precisely human insight and activation. The company has made several key hires and promotions to support the practice.

“Our industry often talks about improving patient outcomes and in evolving our Audience Intelligence group we’ve been able to walk the walk. By ensuring every decision is driven by human insights from the start, we can help our clients to provide their patients and HCPs with what they need and want, often before they themselves recognize that need. We’re reaching the holy grail,” said Julie Hurvitz Aliaga, EVP, Innovation, Content and Partnerships. The evolution of stand-alone departments into one holistic group with strategic leadership sends innovation to the forefront by bringing real-time social and attitudinal data together.

Leading the practice is Liz McShea in the role of Group VP, Audience Intelligence. McShea has deep experience in research and social intelligence, having worked on the vendor side at ListenLogic, and later took her passion and skills for research and healthcare to AstraZeneca, where she was instrumental in building their social intelligence practice, a first for the organization. Now with CMI Media Group, McShea is taking all her knowledge of the vendor and client spaces to move research forward for clients. With McShea’s leadership and vast knowledge of the media landscape, the organization will be able to ensure research leads to media KPIs and keeps media outcomes top of mind.

Joining McShea in leadership is Rick Johnson, who will focus on Market Research and Social Intelligence team management as VP, Intelligence Solutions. In his role, Johnson will ensure the Market Research and Social Intelligence teams continue to deliver opportunities leveraging the organization’s best-in-class tools, such as CheckUp and Media Vitals(TM) research, which have become the gold standard for strategic healthcare audience insights and implementation of innovative approaches. Previously with Aetna/CVS Health, Johnson will continue to expand opportunities for the organization and connect the Market Research to Social Intelligence pillars more closely, threading the needle between research and social data. Rounding out leadership in the group is Fabian Henault, VP, Market Research. As a trusted leader since 2020, Henault will continue to leverage his expansive knowledge and expertise in every aspect of research important to clients to ensure insightful and impactful deliverables.

“Our Audience Intelligence Practice brings unmatched human-centered capabilities to our healthcare clients and enables them to truly put their patients and HCPs at the center at the center of everything they do, while delivering on health and business KPIs,” said Dr. Susan Dorfman, President and CEO, CMI Media Group.

About CMI Media Group

CMI Media Group, a WPP company (NYSE: WPP, http://www.wpp.com), is a full-service media agency focused solely on health, wellness, and pharmaceutical marketing. CMI Media Group’s core offerings include Audience Strategy, Planning, Development, and Insights; Data and Analytics; Buying and Investment; and Direct Response and Customer Experience. As the leading media resource for the world’s top healthcare companies, CMI Media Group brings together leading technology, data, and talent to deliver seamless capabilities for clients. CMI Media Group has been recognized as a leader in DE&I, talent retention and employee development as well as one of the industry’s best places to work. To apply for a position within our teams visit https://cmimediagroup.com/careers/

Share article on social media or email:

Leva Clinic, chronic pain and medical cannabis leaders, raise $3.5m to transform treatment for UK pain patients


“Leva’s unique patient centric platform is delivering for our patients, and with this investment we intend to further increase our reach across the UK and continue to build our offering through digital access.”Eric Bystrom, Leva co-founder and CEO

Leva Clinic has announced that it has secured $3.5m USD (£3m GBP) of funding from Óskare Capital and Justin Hartfield to accelerate innovation in medical cannabis therapeutics and scale the delivery of digital solutions for chronic pain patients.


  • Leva Clinic (“Leva”) operates the UK’s first online clinic for chronic pain, owns one of the UK’s leading brands of medical cannabis (Satoline), and is a founding member of the largest observational medical cannabis study in the UK (Project Twenty21)
  • Justin Hartfield, founder of Weedmaps, one of the world’s largest integrated cannabis technology platforms, has led a $3.5m USD (£3m GBP) investment in Leva alongside Óskare Capital, a European medical and pharmaceutical cannabis fund.
  • Funding will grow the clinic’s reach, strengthen and broaden partnerships with the NHS and other healthcare providers, and improve ongoing patient experience with a mobile app.

One quarter of adults in the UK are living with a pain condition that has lasted over three months, with chronic pain having been dubbed a “silent epidemic”. Pain costs the UK economy significantly more than cancer and heart disease, almost as much as diabetes and obesity costs. A lack of personalised treatment options and difficulties in accessing clinical support currently prevents millions of adults from living a life without pain, and fueling a surge in opioid-related deaths.

Established in 2019, Leva Clinic is the UK’s first online clinic for people living with chronic pain. Regulated by the Care Quality Commission. Leva’s services are accessible through the Boots Health Hub, and the clinic also has live partnerships with several NHS trusts to deliver digital therapeutic services and consultant-led patient care plans.

Justin Hartfield, who founded global cannabis technology platform Weedmaps in 2008, makes the investment via his private investment office 2420 Partners. The investment is the first for 2420 in the UK and the second in Europe. He said:

“Our investment in Leva is perfectly aligned with our goal to support emerging businesses in the pain management space globally. Leva is on the path to being a market leader in delivering innovative pain management solutions by industry-leading pain experts in the UK. We are excited to partner with the company in its next chapter of growth.”

Leva is a founding member of Project Twenty21, the largest observational medical cannabis study in the UK. Leva’s Satoline range of medical cannabis-based medicines is part of the formulary for the trial, gathering evidence on the efficacy of medical cannabis-based medicines.

Leva is also one of three suppliers participating in the ‘I Am Billy’ Foundation RESCAS program (Refractory Epilepsy Specialist Clinical Advisory Service), set up in 2020 following a legal challenge brought by campaigner Charlotte Caldwell against the UK government. It provides a much-needed route to NHS-funded medical cannabis for people under the age of 18 affected by refractory epilepsy.

Leva co-founder and CEO Eric Bystrom said:

“Leva’s unique patient centric platform is delivering for our patients, and with this investment we intend to further increase our reach across the UK and continue to build our offering through digital access. Justin’s experience in developing digital offerings coupled with Oskare’s life sciences expertise make them the perfect partners for this next stage of our journey.”

Óskare Capital is a European medical and pharmaceutical cannabis fund, unlocking the endocannabinoid system through Life Sciences and Deep Tech.

Dr John Rogers, Neurologist and co-founder of Óskare, on joining Leva’s board said:

We have been impressed by Leva’s approach to patient care, also affirmed by their NHS contracts and recent CQC report. Leva has assembled a highly experienced team of pain management experts, and we are excited to help Leva make these patient services available across the UK.”

Oliver Lamb, Co-Founder and Investment Manager at Óskare Capital, said:

“We are excited about our investment in Leva and their much needed pain management platform. One of the key issues that Óskare Capital seeks to address in the medical cannabis market is patient access, and Leva are breaking down the barriers for those patients most in need. Having been in discussions with the Leva team for over a year, we have been continually impressed by their vision and dedication.”

Dr Arun Bhaskar, Consultant in Pain Medicine and President of the British Pain Society, will also join the board as an independent director. He adds:

“The dedication of the team to both best clinical practice and patient care is resulting in excellent patient outcomes”

ENDS

Share article on social media or email:

Schlafender Hase® releases TVT version 11 with more power and enhanced user-friendliness


“The release of TVT 11 significantly strengthens our capabilities in terms of verifying graphics, and further positions Schlafender Hase as an attractive provider of powerful solutions in industries that are highly graphics-driven,” explains Francisco Baraona, co-CEO of Schlafender Hase.

Schlafender Hase® today announced the release of TVT 11, a new version of its industry-leading proofreading software. Upgraded technology, new functionalities and an enhanced user interface make TVT 11 the most powerful and user-friendly version of Schlafender Hase’s flagship product TVT® released to date.

The powerful capabilities of TVT version 11 (based on 64-bit technology) allow users to quickly and easily upload and process documents of virtually any size. The only limit now is a user’s own hardware performance. Benchmarking conducted by Schlafender Hase shows that image matching accuracy and overall speed have increased by up to 20 and 15 percent respectively, with significantly faster file loading and comparison times.

Among the new features is an option to automatically dismiss identical images that recur throughout a document. This saves time by eliminating the need to manually remove identical images. Users can also change window size and layout more easily to suit their preferences and the task at hand. Furthermore, toolbars, buttons and icons have been refreshed with an enhanced look and feel. Other changes include the upgrading of TVT Spelling® dictionaries to the most recent editions, including an updated version of Stedman’s Medical Dictionary®. The TVT Barcode® module now includes capabilities for GS1 DataBar Stacked symbology.

“Many of the features integrated into TVT 11 are the product of our strong engagement with our customers,” explains Frank Hessler, founding CEO of Schlafender Hase. “Our focus in this new version has been two-fold. First, enhancing powerful capabilities that make TVT faster and even more efficient when customers are working with large, complex documents. Second, building on user experience to increase the overall speed, comfort and ease of verifying text, artwork and barcodes.”

“The release of TVT 11 significantly strengthens our capabilities in terms of verifying graphics, and further positions Schlafender Hase as an attractive provider of powerful solutions in industries that are highly graphics-driven,” explains Francisco Baraona, co-CEO of Schlafender Hase.

About Schlafender Hase:

Schlafender Hase leads the way in intelligent, automated text and graphic proofreading solutions. With its flagship product, TVT®, users can quickly compare source content with output formats, detecting changes and deviations prior to publication.

Schlafender Hase serves regulated industries across the globe. Clients include the world’s leading pharmaceutical and medical device companies, as well as healthcare regulatory bodies. The continued success of Schlafender Hase is based on delivering quality products and a strong understanding of customer pain points. Our easy-to-use products reduce proofreading workloads, assure the quality of printed and online materials, and mitigate the risk of costly errors.

Founded in 2001, Schlafender Hase GmbH is headquartered in Frankfurt am Main, Germany, with a subsidiary in the US. More at: http://www.schlafenderhase.com

Share article on social media or email:

Chris Duignan Joins Flourish Research as Chief Financial Officer


Photo of Chris Duignan, CFO of Flourish Research

Chris Duignan, CFO of Flourish Research

“I’m excited to join the Flourish team and work with top-notch, seasoned pharmaceutical services professionals during this time of company-wide growth.” -Chris Duignan, CFO

Chris Duignan has been named Chief Financial Officer of Flourish Research, a diversified clinical trial company designed to acquire, operate, and integrate large, best-in-class clinical research sites with expertise in studies spanning Phases I-IV.

Mr. Duignan will build the financial infrastructure, lead financial operations, and integrate the acquisitions of the rapidly growing organization. He is a highly experienced senior financial executive with more than 25 years of public and private company experience, including 14 years in the life sciences industry.

Mr. Duignan was most recently a VP of Finance at an independent clinical research network comprised of 21 wholly owned clinical sites. Chris previously spent six years as the VP of Finance at the New York Genome Center, building the financial architecture of the DNA sequencing center.

“Chris brings with him a deep understanding of our industry and the ability to leverage financial management and reporting to help research sites thrive,” said Reinhold Schulz, Chief Executive Officer of Flourish. “We are fortunate to have him on the leadership team to guide us during our time of expansion.”

Chris Duignan stated, “I’m excited to join the Flourish team and work with top-notch, seasoned pharmaceutical services professionals during this time of company-wide growth.”

Mr. Duignan spent the first four years of his career at PricewaterhouseCoopers, holds a Bachelor of Science in Accounting from Fairfield University, and spent six years in the Marine Corps Reserves.

About Flourish Research:

Flourish Research is a leading clinical trial organization, created to strategically acquire, create, and operate the best clinical trial sites in North America. Flourish sites started as some of the most recognized trial sites in the industry including Clinical Trials of Texas, Excel Medical Clinical Trials, Clinical Sites Partners, Keystone Clinical, and Great Lakes Clinical Trials.

Flourish sites conduct Phase I-IV studies across therapeutic areas where they have deep expertise, including Cardiology/Metabolic Disease/Renal, CNS, Pulmonology and Vaccines. Flourish key investigators are full-time, dedicated to research at sites that are large and highly experienced.

Share article on social media or email:

Lineal Wins the Relativity Innovation Award for Best Innovation Solution Provider


Lineal Wins the 2022 Relativity Innovation Award for Best Innovation Solution Provider

“Achieving this honor two years in a row energizes us to work harder and partner greater as we strive to achieve our mission of reshaping the litigation services space.”

Lineal, a global legal data services and technology company leveraging AI and process-driven workflows for law firms and corporations, has, for the second year in a row, been awarded the 2022 Relativity Best Innovation Solution Provider Award for their AI suite of Relativity enhancements. The results were announced during Relativity Fest on October 27th.

Each year Relativity recognizes organizations and individuals who build innovative solutions, break down barriers for technology in the practice of law, move eDiscovery forward, and take Relativity to the next level. Winners in the technology categories are organizations using the Relativity platform in creative ways—solving difficult or unique challenges within and outside of eDiscovery.

“Lineal’s clients are the force that drives our innovation, partnering with us to design solutions to their most pressing discovery problems,” said Damon Goduto, Partner at Lineal. “Achieving this honor two years in a row energizes us to work harder and partner greater as we strive to achieve our mission of reshaping the litigation services space.”

Relativity specifically recognized Lineal for its AI-enabled applications Lineal Amplify and Lineal Images, applications that empower litigators and corporate in-house teams to visualize their data, repurpose workflows, speed evidence retrieval, and accelerate the discovery process.

Lineal’s full application suite includes:

Amplify – A Relativity workflow automation tool which brings organization and structure to the chaos of modern litigation by providing a framework for strategic decision-making on a single engagement or across a portfolio of matters. Amplify provides case teams to repurpose their processes and workflows across matters, supplies deep metrics at a glance, with automation and notifications built within.

Lineal Images – A Relativity integrated AI-powered review interface for viewing, classifying, and producing images and other graphics-based content in both SaaS (RelativityOne) and on-prem deployments. Lineal Images allows users to review images as tiles in logical groupings based on their content – landscapes, cityscapes, worksites, colors, etc. — and then tag those images and their duplicates.

Lineal PrivFinder (LPAi) – A proprietary privilege identification application built for Relativity, Lineal PrivFinder immediately identifies and scores privilege documents. LPAi begins by analyzing communication data (i.e., law firm domains, the role of the sender, keywords, etc.) and then inputs case-specific information (communications involving aligned and adverse parties and lawyers, in-house legal staff, and professional signatures, etc.) to provide the likelihood of a document being privileged. Next-generation AI machine learning is informed by a human expert to catch indicators of privilege with uncanny accuracy and continues to improve iteratively with subsequent use.

Lineal ChatCraft – A bespoke Lineal Relativity enablement tool, ChatCraft Enables users to tag and review chat data (Google Chat, Teams, Slack, SMS, etc.) on the per chat, per day, or even individual message level. ChatCraft allows users to keep track of important documents by associating attachments with conversations. Further, users can visualize chat history over timelines, revealing key trends in communications. As a result of ChatCraft, the production of collaborative data is substantially smoother, as the application allows you to export only the relevant messages without redacting countless other unresponsive messages.

Lineal ECAi/Bot Detection – Designed to eliminate junk and provide upfront logical culling. Bot detector technology identifies “bot” generated messages in the review database. This technology is not just a domain analysis; it also compares the ratio of sent messages by certain domains to the number of times those messages were replied to or forwarded, essentially identifying one-way communicators. ECAi culls, on average, an additional 15% of all communications docs. Additionally, ECAi identifies intense conversations through sentiment analysis, and communication patterns are brought to the surface.

Lineal Snippets – An exclusive Lineal Relativity application, Snippets provides a field within Relativity that displays keyword hits in context, enabling reviewers to code multiple documents at once without the necessity to open them fully.

Lineal Ai Threading Application (LTAi) – LTAi identifies the most inclusive document and delivers this information inside of Relativity. LTAi doubles standard suppression rates of communication documents (email, Slack, messages, Teams, etc.) compared to Relativity threading. The average culling performance with LTAi is approximately 30%.

# # #

About Lineal

Lineal is a global legal data services organization leveraging AI and process-driven workflows to solve litigation, privacy, compliance, DSAR, information governance, and cyber issues for law firms and corporations. Headquartered in Dallas, and with offices throughout the North and South Americas, Europe, APAC and the Middle East, Lineal has been delivering pioneering solutions since 2009

For media inquiries, please contact:

marketing@linealservices.com

Connect with us on LinkedIn and Twitter.

About Relativity

Relativity makes software to help users organize data, discover the truth and act on it. Its SaaS product RelativityOne manages large volumes of data and quickly identifies key issues during litigation and internal investigations. The AI-powered communication surveillance product, Relativity Trace proactively detects regulatory misconduct like insider trading, collusion and other non-compliant behavior. Relativity has more than 300,000 users in approximately 40 countries serving thousands of organizations globally primarily in legal, financial services and government sectors, including the U.S. Department of Justice and 198 of the Am Law 200. Relativity has been named one of Chicago’s Top Workplaces by the Chicago Tribune for 10 consecutive years. Please contact Relativity at sales@relativity.com or visit http://www.relativity.com for more information.



SmartTRAK Advances Medtech Market Insights Platform; Announces New Modules for Wound Care and Orthopedic/Spine Injectables


SmartTRAK Logo

“SmartTRAK has a long history of being the trusted source for our clients … We are continuously expanding the SmartTRAK platform to cover new and emerging markets of high value to our subscribers and offer unique and differentiated analytical tools.” – Sharon O’Reilly, CEO

SmartTRAK, the leading global Medtech business and market insights platform in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces the expansion of its solutions portfolio focused on new market coverage for Wound Debridement and Injectables for spinal disc degeneration and osteoarthritis (OA) of the knee.

SmartTRAK is an Insights-as-a-Service platform that equips customers with real-time, accurate market, company and product insights from hundreds of carefully curated data sources. The solution includes rich content provided through a SaaS platform and includes daily updates, tools and dashboards along with direct access to market analysts and expert advisory services.

Wound Debridement, a newly covered segment offered on the SmartTRAK platform, is foundational to wound healing and the success of every advanced wound care product. According to Wound Care market expert and General Manager Gary Delhougne, “our new module will cover the full scope of the debridement market opportunity and will be beneficial to companies directly participating or contemplating entering into the debridement space.” The Wound Debridement module is now widely available to customers.

SmartTRAK is addressing the explosive growth in the Injectables arena, specifically in the areas of osteoarthritic knee pain, discogenic back pain and degenerative disc disease. According to Elise Wolf, General Manager of Orthopedics and Enabling Technologies, “the potential US market for Disc Injectables is over $50B annually, while the next generation OA Injectables exceeds $10B annually. Our market experts have been keeping a finger on the pulse of this dynamic growth sector and clients can now leverage the SmartTRAK platform for strategic planning and product development related to injectable technologies.” The Disc Injectables module is currently available and the Knee OA module will be launched by the end of 2022.

“SmartTRAK has a long history of being the trusted source for our clients for relevant, up-to-date and comprehensive market coverage and critical insights for strategic decision-making,” says CEO Sharon O’Reilly. “We are continuously expanding the SmartTRAK platform to cover new and emerging markets of high value to our subscribers and offer unique and differentiated analytical tools that help our customers innovate while achieving economies of scale with one comprehensive solution. The Debridement and Injectables market expansions are examples of how SmartTRAK helps our customers stay on the forefront of market advancements.”

SmartTRAK is innovating to serve the business intelligence needs for more than 75 global Medtech customers, which include most of the leading Orthopedic and Wound Care companies. “We have an aggressive product roadmap that includes further expansion into new markets as well as significant investment in developing a new suite of Data Insights tools for product, procedure, pricing and sales targeting built off of granular data sources,” shares Chief Growth Officer Linda Bernier. “Our customers are drowning in clunky data files and consistently look to SmartTRAK as their primary source for meaningful insights and real-time tools that can be accessed 24×7 by leaders across their enterprise.”

Starting in 2023, SmartTRAK will also be offering customers new capabilities for tracking and analyzing the Ambulatory Surgical Center (ASC) market along with other tools that offer strategic insights from CMS and other publicly available and commercial data sources.

About SmartTRAK

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. For more information visit http://www.SmartTRAK.com and follow us on LinkedIn.

Share article on social media or email:

COFEPRIS Certifies Valeo II™ Silicon Nitride Interbody Line


CTL Amedica is the world’s exclusive provider of silicon nitride spine products.

The Valeo II silicon nitride interbody line provides many advantages for surgeons and their patients, and we are thrilled to start marketing the devices in Mexico.

The Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the agency charged with overseeing the quality of medical devices and products made in and imported into Mexico, has certified the registration of CTL Amedica Corporation’s Valeo II™ silicon nitride interbody line. The registration was made with the assistance of registration partner Minimal Medics S.A de C.V.; and the certification will enable CTL Amedica to commercialize and market the Valeo II silicon nitride interbody line in Mexico.

“The Valeo II silicon nitride interbody line provides many advantages for surgeons and their patients, and we are thrilled to start marketing the devices in Mexico. Silicon nitride is the only material to provide osteointegration, bacteriostatic properties and excellent imaging quality. This is important medical technology and we’re grateful for the opportunity to make it readily accessible in Mexico,” said Daniel Chon, CEO of CTL Amedica.

The certification includes the following Valeo II devices:

  • Valeo II C, Anterior Cervical Interbody Fusion Device
  • Valeo II OL, Bulleted Transforaminal Lumbar Interbody Fusion Device
  • Valeo II TL, Curved Transforaminal Lumbar Interbody Fusion Device
  • Valeo II AL, Anterior Lumbar Interbody Fusion Device
  • Valeo II LL, Lateral Lumbar Interbody Fusion Device

Valeo II interbody devices are made entirely of silicon nitride, an ideal biomaterial. Silicon nitride’s surface chemistry and natural nanostructure topography provide an optimal environment for new bone growth and contribute to its inherent, bacteriostatic behavior. CTL Amedica is the world’s exclusive provider of silicon nitride spine products.

In addition, the Valeo II interbody line is semi-radiolucent with clearly visible boundaries and the products produce no distortion under MRI, as well as, no scattering under CT. These favorable imaging qualities enable a precise view of the implants’ operative placement and postoperative fusion assessment.

CTL Amedica is a forward-thinking medical device design, development and manufacturing company. CTL Amedica maintains a Texas-based headquarters and in-house manufacturing facility, along with a Pennsylvania-based R&D Center of Excellence. A leader in the medical device technology and biomaterials space, CTL Amedica provides a full line of cervical, thoracic and lumbar fusion and fixation products. For more information, visit https://www.ctlamedica.com/.

Share article on social media or email:

American College of Lifestyle Medicine Designates the Ardmore Institute of Health’s Full Plate Living Program a Certified Lifestyle Medicine Program


News Image

More people are living healthier lives and feeling great because of Full Plate Living and the Ardmore Institute’s passion for a future where healthy lifestyles are the preferred method to prevent, treat and reverse chronic diseases.

The American College of Lifestyle Medicine (ACLM) today announced that the Ardmore Institute of Health’s (AIH) Full Plate Living program has earned Certified Lifestyle Medicine Program designation. The designation recognizes, supports and encourages the adoption of evidence-based health intervention programs that meet rigorous review requirements and standards for offering lifestyle modification to address chronic disease.

Lifestyle medicine is a medical specialty that uses therapeutic lifestyle interventions as a primary modality to treat chronic conditions including, but not limited to, cardiovascular diseases, type 2 diabetes, and obesity. Lifestyle medicine-certified clinicians are trained to apply evidence-based, whole-person, prescriptive lifestyle change to treat and, when used intensively, often reverse such conditions. Applying the six pillars of lifestyle medicine—a whole-food, plant-predominant eating pattern, physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connections—also provides effective prevention for these conditions.

Full Plate Living is a nutrition education program provided as a free service by AIH. The program helps people add more whole, unprocessed fiber foods into their diet — a friendly approach to diet improvements that can lead clients to meaningful changes in their health.

About 90 percent of Americans fail to meet the minimum daily fiber recommendations of 25 grams for women and 38 grams for men, with the average intake being only around 16 grams per day. Full Plate Living promotes a high-fiber approach to healthy eating through the consumption of fruits, vegetables, beans and legumes, whole grains, nuts and seeds.

A high-fiber diet is associated with decreased risk of cardiovascular disease, coronary artery disease, type 2 diabetes, and gastric, pancreatic, breast and colorectal cancers, as well as overweight and obesity. A high-fiber diet has also been shown to significantly lower total and LDL cholesterol and triglycerides, and it is associated with decreased risk of depression.

There are two ways that individuals and clinicians can access Full Plate Living services and programs. Clinicians can refer patients to the Full Plate Living online membership at fullplateliving.org. Sign-up provides individuals with access to nutrition programs, healthy lifestyles workshops, recipes, a weekly email and a supportive online community. The self-paced nutrition program allows individuals to implement changes at their next meal. Also available at no cost are group program materials, including a facilitator and participant guide. The group program provides a simple-to-follow guide for facilitation through eight sessions. The online membership provides ongoing support when the group-facilitated program ends.

The ACLM program certification designation is offered at three different levels based upon evaluation scores—Honorable Mention, Certified and Gold Certified. The levels are based on factors including years in operation, number of participants, number of organizations using the program, the inclusion of all lifestyle medicine pillars, intervention trials, duration of active treatment, amount of staff contact and follow-up, positive health metrics achieved and participant testimonials.

“ACLM is very proud to recognize the Ardmore Institute of Health’s Full Plate Living as a certified lifestyle medicine program,” said ACLM President Cate Collings, MD, MS, FACC, DipABLM. “More people are living healthier lives and feeling great because of Full Plate Living and the Ardmore Institute’s passion for a future where healthy lifestyles are the preferred method to prevent, treat, and reverse chronic diseases.”

Full Plate Living is the fifth program to earn certification designation from ACLM. The others are: Pivio – the Complete Health Improvement Program, Chanwuyi Lifestyle Medicine Program, The Lift Project and Rochester Lifestyle Medicine Institute’s 15-Day WFPB Jumpstart.

About ACLM

The American College of Lifestyle Medicine is the nation’s medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based, and equitable healthcare delivery system, leading to whole-person health. ACLM educates, equips, empowers and supports its members through quality, evidence-based education, certification, and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

About Ardmore Institute of Health

Ardmore Institute of Health works for a future where healthy lifestyles will be the preferred method to prevent, treat and reverse chronic diseases such as diabetes and obesity. Since 1947 the organization has been promoting lifestyle change as a means to help people achieve a more healthy and fulfilling life. The Institute is eager to address health inequities and positively influence the social determinants of health in all communities. AIH provides grants to projects that support this mission as well as a free nutrition improvement program called Full Plate Living. Full Plate Living helps people add more whole plant-based foods to meals they’re already eating. It’s a small-step approach that can lead to big health outcomes.

Share article on social media or email:

Houston Emergency Room Physician Raises Alarm About Surge in Respiratory Syncytial Virus (RSV) Infections in Texas


SignatureCare Emergency Center, Plano, TX

SignatureCare Emergency Center, Plano, TX

We are seeing an increase in pediatric and adult RSV infections in our emergency rooms throughout Texas. RSV pops up during the fall and winter cold seasons every year and infects younger kids and adults over 65 years old, but this year, the rate of infection is unprecedented.

As Texans let their guards down and ditch habits that helped keep COVID-19 at bay, a Houston emergency room physician is raising alarm about a potential surge in Respiratory Syncytial Virus or RSV, flu, and COVID infections this winter.

Dr. Hashibul Hannan, a board-certified emergency room physician, and founding member of Houston, TX-based SignatureCare Emergency Center, said this week that SignatureCare ER physicians are seeing a surge in emergency room visits due to RSV infections.

“We are seeing an increase in pediatric and adult RSV infections in our emergency rooms throughout Texas. RSV pops up during the fall and winter cold seasons every year and infects younger kids and adults over 65 years old, but this year, the rate of infection is unprecedented.

“If this continues, coupled with the potential for an increase in COVID and flu infections, Texans could see a ‘tripledemic’ surge this winter,” he said.

Respiratory Syncytial Virus, like COVID-19, is spread when an infected person coughs or sneezes, thereby spreading the virus droplets, which can get into nostrils and eyes, or when someone touches a surface that has the virus on it.

“We can lower the rate at which RSV is spreading just by doing simple things like washing our hands frequently, covering our noses and mouths when we sneeze or cough, using hand sanitizer often, and keeping our distance from others, just like we did at the height of COVID infections,” Hannan added.

He said SignatureCare Emergency Center physicians can diagnose and treat all kinds of viruses, including Rhinovirus, Influenza (flu), Parainfluenza, and RSV.

“We can diagnose and treat all these viruses, including flu and RSV, in our emergency rooms. Our physicians have the experience to quickly diagnose and treat them,” he said.

The Centers for Disease Control and Prevention (CDC) reported this week that Respiratory Syncytial Virus (RSV) infections are increasing exponentially in multiple U.S. regions, with some regions nearing seasonal peak levels.

“CDC surveillance has shown an increase in RSV detections and RSV-associated emergency department visits and hospitalizations in multiple U.S. regions, with some regions nearing seasonal peak levels. Clinicians and public health professionals should be aware of increases in respiratory viruses, including RSV,” a statement posted on the CDC’s website said.

The CDC said that RSV, the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs), can be serious for infants and older adults.

“Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults.

“Each year in the United States, RSV leads to, on average, approximately 58,000 hospitalizations with 100-500 deaths among children younger than 5 years old and 177,000 hospitalizations with 14,000 deaths among adults aged 65 years or older,” according to the CDC.

Symptoms of RSV in children and adults include runny nose, decrease in appetite, coughing, sneezing, fever, and wheezing.

To find the SignatureCare Emergency Center location near you, go to our ER locations page. Our emergency rooms are open 24/7.

About SignatureCare Emergency Center

Houston, TX-based SignatureCare Emergency Center owns 24-hour emergency centers throughout Texas, including nine ER locations in the Houston area (Montrose, Houston Heights, Cypress/FM 1960, Copperfield, Memorial City, Westchase, Bellaire, Mission Bend/Sugar Land, and Stafford), Atascocita/Humble, Killeen, Austin, College Station/Bryan, Paris, Midland, Odessa, Texarkana, Spring, Plano, and Lewisville, TX.